Opendata, web and dolomites

TiDrugArchitectures SIGNED

Highly Competent and Safe Titanium(IV) Therapeutic Frameworks that are Cancer Targeted based on Complex 1, 2, and 3D Chemical Architectures

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 TiDrugArchitectures project word cloud

Explore the words cloud of the TiDrugArchitectures project. It provides you a very rough idea of what is the project "TiDrugArchitectures" about.

flexible    customized    maintaining    incorporating    dendritic    bulk    selectivity    conjugates    group    penetrating    cancer    linked    centers    tshuva    linear    stable    anticancer    permeability    polymeric    peptides    possibly    bio    pt    vivo    action    donors    rigid    assemblies    optimal    options    medicinal    designed    tumor    entities    chemical    directions    drugs    therapeutic    release    accessibility    superior    active    cages    redox    selective    synergistic    ph    enhanced    custom    phenolato    small    metal    sensitive    unlimited    vitro    water    transport    tiiv    types    steric    frameworks    sites    hydrophilicity    dependent    direct    markedly    moieties    complexes    dissociation    penetration    stability    steroid    shown    mechanism    species    bioactive    mystery    bonds    desired    combination    safe    cells    constructed    analyzing    selectively    cell    binding    biological    interaction    compound    hormone    yield    derivatives    biochemistry    molecules    3d    unraveling    agents    biocompatible    combine    geometries    multiple    cellular    conjugate   

Project "TiDrugArchitectures" data sheet

The following table provides information about the project.

Coordinator
THE HEBREW UNIVERSITY OF JERUSALEM 

Organization address
address: EDMOND J SAFRA CAMPUS GIVAT RAM
city: JERUSALEM
postcode: 91904
website: www.huji.ac.il

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Total cost 2˙000˙000 €
 EC max contribution 2˙000˙000 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2015-CoG
 Funding Scheme ERC-COG
 Starting year 2016
 Duration (year-month-day) from 2016-06-01   to  2021-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    THE HEBREW UNIVERSITY OF JERUSALEM IL (JERUSALEM) coordinator 2˙000˙000.00

Map

 Project objective

This proposal aims to develop custom designed anticancer therapeutic frameworks that are effective, stable, safe, and tumor targeted, based on the biocompatible TiIV metal. The Tshuva group has established that water stable phenolato TiIV complexes are especially effective as anticancer agents both in vitro and in vivo, with markedly reduced side effects. Optimal derivatives will be developed to combine activity, stability, and biological accessibility, by maintaining small steric bulk while incorporating strong binding donors and hydrophilicity. The mechanism of action will be investigated by chemical and biological methods, including analyzing bio-distribution, cellular pathways and targets, and interaction with bio-molecules. Specifically, the active metal centers will be linked to bioactive moieties through redox-sensitive S–S bonds to enable tumor targeting. Cell penetrating peptides will facilitate cellular penetration for redox-dependent release of the active species selectively in cancer cells; steroid moieties will direct selectivity to hormone-dependent cancer cell types. Since the combination of TiIV- with Pt-based drugs has shown synergistic effects, multi-active entities will include two or more metal centers, possibly also linked to a transport unit. In addition to linear conjugates, polymeric and dendritic assemblies, exploiting the enhanced permeability of cancer cells, will be constructed with theoretically unlimited options for targeted delivery of multiple active sites. Most importantly, flexible well-defined redox-sensitive cages, as well as rigid pH sensitive complex cages, constructed with customized 3D geometries, will enable specific targeting of any active compound or conjugate and selective dissociation only where desired. This study should yield superior anticancer drugs, while unraveling the mystery of their complex biochemistry, and will contribute to the development of novel chemical and medicinal research directions and applications.

 Publications

year authors and title journal last update
List of publications.
2018 Maya Miller, Edit Y. Tshuva
Racemic vs. enantiopure inert Ti( iv ) complex of a single diaminotetrakis(phenolato) ligand in anticancer activity toward human drug-sensitive and -resistant cancer cell lines
published pages: 39731-39734, ISSN: 2046-2069, DOI: 10.1039/c8ra08925f
RSC Advances 8/69 2019-08-29
2018 Avia Tzubery, Naomi Melamed-Book, Edit Y. Tshuva
Fluorescent antitumor titanium( iv ) salen complexes for cell imaging
published pages: 3669-3673, ISSN: 1477-9226, DOI: 10.1039/c7dt04828a
Dalton Transactions 47/11 2019-05-10

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TIDRUGARCHITECTURES" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TIDRUGARCHITECTURES" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

ERC VP CSA (2018)

Support to the Vice-Presidents of the ERC Scientific Council 2018

Read More  

CellProbe (2019)

CellProbe: Microfluidic probe for simultaneous tagging and extraction of single cells

Read More  

MAGIC-SWITCH (2019)

MAGIC-SWITCH: Magnetic Switch Controlled with Voltage

Read More